PAS
DYN icon

Point72 Asia (Singapore)’s Dyne Therapeutics DYN Stock Holding History

Point72 Asia (Singapore)’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,805
Closed -$186K – 982
2025
Q1 		$186K Buy
+17,805
New +$255K 0.05% 288

Other funds holding DYN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asia (Singapore)'s DYN Position: Q2 2025 in Review

Point72 Asia (Singapore) sold out of Dyne Therapeutics (DYN) in Q2 2025, closing a stake of 17,805 shares — an estimated $186K sold.

Point72 Asia (Singapore) first reported a position in DYN in Q1 2025 and held it in 1 quarter. The position peaked at $186K in Q1 2025. 197 funds tracked by Wall St. Rank hold DYN as of Q2 2025.

  • Point72 Asia (Singapore) reported no remaining Dyne Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 17,805 Dyne Therapeutics shares in Q2 2025, an estimated $186K.
  • Point72 Asia (Singapore) first reported a position in Dyne Therapeutics in Q1 2025 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s Dyne Therapeutics position peaked at $186K in Q1 2025.
  • 197 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2025, filed 14 Aug 2025.